Evolus (EOLS)Frazier Life Sciences Management, L.P. added to its stake +195K shares

2.63M

Shares reported · +195K vs prior quarter

0.48%

Disclosed portfolio weight

$16.2M

Reported value

Holdings as of

Sep 30, 2025

Filed

Nov 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results

What came next

1. Jan 9, 2026Company filing · Form 8-K · ResultsReported its results
2. Mar 3, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)
3. Mar 13, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 13, 2026 , in order to restore balance among the classes of directors, the Board approved actions to reclassify Vikram Malik from Class III to Class II.”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Evolus

For Evolus, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EOLS page.

How this filing works

• SEC Form 13F

Other disclosures at Evolus

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRNov 17, 2025
• SEC Form 13F-HRNov 14, 2025
• SEC Form 4Aug 26, 2025
• SEC Form 4Aug 18, 2025
• SEC Form 13F-HRAug 14, 2025

Everything OQRO holds on this company is on its EOLS page.